Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8202643 | 1.00 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL5661362 | 0.93 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL6006120 | 0.93 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL6007100 | 0.89 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL6006329 | 0.89 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL6005399 | 0.89 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6004079 | 0.89 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL9417454 | 0.89 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL6007168 | 0.88 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL6005542 | 0.88 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. | 2006-12-21 | — | — | US | disclosed |
| EP-1014966-B1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | ALLELIX NEUROSCIENCE INC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7019024-B2 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1014966-A4 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | ALLELIX NEUROSCIENCE INC (US) | 2001-10-04 | — | — | EP | disclosed |
| US-20010012857-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | NPS PHARMACEUTICALS, INC. | 2001-08-09 | — | — | US | disclosed |
| US-6191165-B1 | ANTIDEPRESSANTS; SCHIZOPHRENIA; ALZHEIMER'S DISEASE; ANTIEPILEPTIC AGENTS | ALLELIX NEUROSCIENCE INC. | 2001-02-20 | — | — | US | disclosed |
| EP-1014966-A1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Allelix Neuroscience Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1997045115-A1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | TROPHIX PHARMACEUTICALS, INC. (US) | 1997-12-04 | — | — | WO | disclosed |
| US-5320825-A | Psychological disorders | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1994-06-14 | — | — | US | disclosed |
| WO-1992019210-A2 | SEROTININ REUPTAKE INHIBITORS FOR S.P.E.C.T IMAGING | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1992-11-12 | — | — | WO | disclosed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4313896-A | ANTIDEPRESSANTS, PSYCHOTROPIC AGENTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4314081-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4194009-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
| US-4018895-A | Aryloxyphenylpropylamines in treating depression | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC18A2, SLC6A1, SLC6A11 | SLC6A4 9/4885SLC6A2 4/4885SLC6A3 8/4885 |
| US-20010012857-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC6A1, SLC18A2, SLC6A11 | SLC6A4 14/4885SLC6A2 5/4885SLC6A3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.